{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:31:58Z","timestamp":1783031518955,"version":"3.54.6"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The incidence of AML increases with age. The implementation of reduced intensity conditioning and progress in supportive care enabled to perform allo-HSCT in elderly patients. The main objective of the study was to assess the safety and efficacy of allotransplantation in elderly AML.Forty nine patients (33 males) at median age of 68\u00a0years were identified. Data on patients\u2019 and transplant\u2019s related variables were retrieved from our local transplant registry. Most patients (65%) were transplanted from 10\/10-HLA or 9\/10-HLA matched unrelated donor, seven patients (14%) received stem cells from matched related donor and ten patients (20%) from haploidentical donor. All patients received reduced-intensity conditioning (RIC). Peripheral blood was a source of stem cells in all patients except one (98%). Acute GVHD developed in 22 patients (44%) with 5 individuals presenting grade III-IV. CMV reactivation was demonstrated in 19 patients (39%) till day\u2009+\u2009100. In total, 22 patients (45%) have died. The main causes of death included infectious complications (<jats:italic>n<\/jats:italic>\u2009=\u20099), relapse with subsequent chemotherapy resistance (<jats:italic>n<\/jats:italic>\u2009=\u20097), steroid-resistant GvHD (<jats:italic>n<\/jats:italic>\u2009=\u20094) and other causes (<jats:italic>n<\/jats:italic>\u2009=\u20092). Twenty-seven patients (55%) were alive at the last contact, presented full donor chimerism and remained in the complete remission. The probability of OS and relapse-free survival (RFS) were 57% and 81% at 2\u00a0years, respectively. Older donor age showed negative impact on relapse. CMV reactivation, the severity of acute graft versus host disease and older donor age negatively influenced survival. Allo-HSCT remains a safe, feasible and effective procedure for elderly AML patients.<\/jats:p>","DOI":"10.1007\/s00277-023-05226-1","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T13:03:31Z","timestamp":1681909411000},"page":"1907-1914","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience"],"prefix":"10.1007","volume":"102","author":[{"given":"Katarzyna","family":"Duda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Wieczorkiewicz-Kabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kocl\u0119ga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Zieli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wo\u017aniczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Krzemie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Armatys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3703-1268","authenticated-orcid":false,"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"5226_CR1","unstructured":"SEER Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia. https:\/\/seer.cancer.gov\/"},{"key":"5226_CR2","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A et al (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113:4179\u20134187","journal-title":"Blood"},{"key":"5226_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2141.2010.08470.x","volume":"152","author":"DA Pollyea","year":"2011","unstructured":"Pollyea DA, Kohrt HE, Medeiros BC (2011) Acute myeloid leukaemia in the elderly: a review. Br J Haematol 152:524\u2013542","journal-title":"Br J Haematol"},{"key":"5226_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 recommendations from an international expert panel. Blood 129:424\u2013447","journal-title":"Blood"},{"key":"5226_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden JA, S\u00e1nchez-Ortega I, Corbacioglu S et al (2022) Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 57:1217\u20131239","journal-title":"Bone Marrow Transplant"},{"key":"5226_CR6","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M et al (2017) Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood 130:1156\u20131164","journal-title":"Blood"},{"key":"5226_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ajh.22246","volume":"87","author":"EH Estey","year":"2012","unstructured":"Estey EH (2012) Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87:89\u201399","journal-title":"Am J Hematol"},{"key":"5226_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447","journal-title":"Blood"},{"key":"5226_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/bmt.2011.110","volume":"47","author":"A Gratwohl","year":"2012","unstructured":"Gratwohl A (2012) The EBMT risk score. Bone Marrow Transplant 47:749\u2013756","journal-title":"Bone Marrow Transplant"},{"key":"5226_CR10","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912\u20132919","journal-title":"Blood"},{"key":"5226_CR11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, Lee SJ, Ferrara JL et al (2018) EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 53:1401\u20131415","journal-title":"Bone Marrow Transplant"},{"key":"5226_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141\u20131154","journal-title":"Ann Stat"},{"key":"5226_CR13","unstructured":"R Core Team (2022). R: A language and environment for statistical computing. Version 4.2.0. R Foundation for Statistical Computing, Vienna, Austria"},{"key":"5226_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/sj.leu.2403591","volume":"19","author":"A Shimoni","year":"2005","unstructured":"Shimoni A, Kr\u00f6ger N, Zabelina T et al (2005) Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 19:7\u201312","journal-title":"Leukemia"},{"key":"5226_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.bbmt.2009.12.537","volume":"16","author":"J Koreth","year":"2010","unstructured":"Koreth J, Aldridge J, Kim HT et al (2010) Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 16:792\u2013800","journal-title":"Biol Blood Marrow Transplant"},{"key":"5226_CR16","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.bbmt.2013.06.008","volume":"19","author":"AM Brunner","year":"2013","unstructured":"Brunner AM, Kim HT, Coughlin E et al (2013) Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 19:1374\u20131380","journal-title":"Biol Blood Marrow Transplant"},{"key":"5226_CR17","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/bmt.2016.156","volume":"51","author":"M Pohlen","year":"2016","unstructured":"Pohlen M, Groth C, Sauer T et al (2016) Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (\u2a7e60 years). Bone Marrow Transplant 51:1441\u20131448","journal-title":"Bone Marrow Transplant"},{"key":"5226_CR18","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.bbmt.2019.05.037","volume":"25","author":"O Ringd\u00e9n","year":"2019","unstructured":"Ringd\u00e9n O, Boumendil A, Labopin M et al (2019) Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 25:1975\u20131983","journal-title":"Biol Blood Marrow Transplant"},{"key":"5226_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.bbmt.2019.12.766","volume":"26","author":"J Hsu","year":"2020","unstructured":"Hsu J, Chen Z, Shore T et al (2020) Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biol Blood Marrow Transplant 26:789\u2013797","journal-title":"Biol Blood Marrow Transplant"},{"key":"5226_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/ajco.12188","volume":"10","author":"K Jackson","year":"2014","unstructured":"Jackson K, Kennedy G, Mollee P, Marlton P, Morris K (2014) Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients. Asia Pac J Clin Oncol 10:246\u2013254","journal-title":"Asia Pac J Clin Oncol"},{"key":"5226_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/leu.2015.188","volume":"30","author":"AG Dinmohamed","year":"2016","unstructured":"Dinmohamed AG, Visser O, van Norden Y et al (2016) Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989\u20132012. Leukemia 30:24\u201331","journal-title":"Leukemia"},{"key":"5226_CR22","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.leukres.2015.05.003","volume":"39","author":"JM Bastida","year":"2015","unstructured":"Bastida JM, Cabrero M, Lopez-Godino O et al (2015) Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome. Leuk Res 39:828\u2013834","journal-title":"Leuk Res"},{"issue":"Suppl 1","key":"5226_CR23","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1002\/sctm.12812","volume":"9","author":"E Galamidi-Cohen","year":"2020","unstructured":"Galamidi-Cohen E, Joyce A, Simantov R (2020) Impact of Donor Age on Outcomes in Hematopoietic Stem Cell Transplantation. Stem Cells Transl Med 9(Suppl 1):S7","journal-title":"Stem Cells Transl Med"},{"key":"5226_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbmt.2014.09.021","volume":"21","author":"AR Rezvani","year":"2015","unstructured":"Rezvani AR, Storer BE, Guthrie KA et al (2015) Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 21:105\u2013112","journal-title":"Biol Blood Marrow Transplant"},{"key":"5226_CR25","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3324\/haematol.2016.147645","volume":"101","author":"HT Kim","year":"2016","unstructured":"Kim HT, Zhang MJ, Woolfrey AE et al (2016) Donor and recipient sex in allogeneic stem cell transplantation: what really matters. Haematologica 101:1260\u20131266","journal-title":"Haematologica"},{"key":"5226_CR26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.bbmt.2014.12.018","volume":"21","author":"P Kongtim","year":"2015","unstructured":"Kongtim P, Di Stasi A, Rondon G et al (2015) Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? Biol Blood Marrow Transplant 21:713\u2013719","journal-title":"Biol Blood Marrow Transplant"},{"key":"5226_CR27","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1182\/bloodadvances.2019000814","volume":"4","author":"S Kaito","year":"2020","unstructured":"Kaito S, Nakajima Y, Hara K et al (2020) Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. Blood Adv 4:1051\u20131061","journal-title":"Blood Adv"},{"key":"5226_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","volume":"9","author":"M Boeckh","year":"2003","unstructured":"Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9:543\u2013558","journal-title":"Biol Blood Marrow Transplant"},{"key":"5226_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00277-014-2190-1","volume":"94","author":"JE Jang","year":"2015","unstructured":"Jang JE, Kim SJ, Cheong JW et al (2015) Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann Hematol 94:275\u2013282","journal-title":"Ann Hematol"},{"key":"5226_CR30","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood-2016-04-713644","volume":"128","author":"AH Elmaagacli","year":"2016","unstructured":"Elmaagacli AH, Koldehoff M (2016) Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia. Blood 128:456\u2013459","journal-title":"Blood"},{"key":"5226_CR31","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M et al (2016) Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 127:2427\u20132438","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05226-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T06:04:17Z","timestamp":1686549857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05226-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5226"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05226-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"29 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective study and the consent of Ethics Committee was not required. Allogeneic hematopoietic stem cell transplantation remains a standard of care for AML patients as per EBMT recommendations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients and is available per request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"none","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}